Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.

Ovacik AM, Li J, Lemper M, Danilenko D, Stagg N, Mathieu M, Ellerman D, Gupta V, Kalia N, Nguy T, Plaks V, David Johnson C, Wang W, Brumm J, Fine B, Junttila T, Lin K, Carter PJ, Prabhu S, Spiess C, Kamath AV.

MAbs. 2019 Feb/Mar;11(2):422-433. doi: 10.1080/19420862.2018.1551676. Epub 2018 Dec 17.

2.

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.

Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV.

MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2.

3.

A 31-year-old female with 
a rare cause of recurrent lower lobar collapses.

Banka R, Terrington D, Kamath AV.

Breathe (Sheff). 2018 Jun;14(2):e72-e77. doi: 10.1183/20734735.017318.

4.

Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.

Wang-Lin SX, Zhou C, Kamath AV, Hong K, Koppada N, Saad OM, Carrasco-Triguero M, Khojasteh C, Deng R.

MAbs. 2018 Oct;10(7):1131-1143. doi: 10.1080/19420862.2018.1494478. Epub 2018 Aug 6.

PMID:
30081725
5.

Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC.

Figueroa I, Leipold D, Leong S, Zheng B, Triguero-Carrasco M, Fourie-O'Donohue A, Kozak KR, Xu K, Schutten M, Wang H, Polson AG, Kamath AV.

MAbs. 2018 Jul;10(5):738-750. doi: 10.1080/19420862.2018.1465160. Epub 2018 May 18.

6.

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.

Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR.

Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21.

7.

Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.

Kamath AV.

Drug Discov Today Technol. 2016 Sep - Dec;21-22:75-83. doi: 10.1016/j.ddtec.2016.09.004. Epub 2016 Oct 24. Review.

8.

Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice.

Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, Koppada N, Hong K, Baruch A, Carrasco-Triguero M, Saad O, Mariathasan S, Kamath AV.

MAbs. 2016 Nov/Dec;8(8):1612-1619. Epub 2016 Sep 21.

9.

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.

Stagg NJ, Shen BQ, Brunstein F, Li C, Kamath AV, Zhong F, Schutten M, Fine BM.

Regul Toxicol Pharmacol. 2016 Dec;82:1-13. doi: 10.1016/j.yrtph.2016.10.012. Epub 2016 Oct 20. Review.

PMID:
27773754
10.

Behçet's pulmonary artery aneurysms treated with infliximab and monitored with the 6-min walk test.

Kotecha J, Kamath AV, Mukhtyar C.

Oxf Med Case Reports. 2016 Apr 26;2016(4):94-6. doi: 10.1093/omcr/omw028. eCollection 2016 Apr.

11.

Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.

Gupta P, Kamath AV, Park S, Chiu H, Lutman J, Maia M, Tan MW, Xu M, Swem L, Deng R.

MAbs. 2016 Jul;8(5):991-7. doi: 10.1080/19420862.2016.1167294. Epub 2016 Mar 31.

12.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, Barfield M, Xiao G, Escandon E, Wang W, Rock DA, Chemuturi NV, Moore DJ.

Drug Metab Dispos. 2016 May;44(5):617-23. doi: 10.1124/dmd.115.068049. Epub 2015 Dec 15. Review.

PMID:
26669328
13.

Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.

Couch JA, Zhang G, Beyer JC, de Zafra CL, Gupta P, Kamath AV, Lewin-Koh N, Tarrant J, Allamneni KP, Cain G, Yee S, Ross S, Cook R, Tsai SP, Ruppel J, Ridgway JB, Paluch M, Hass PE, Franklin J, Yan M.

Clin Cancer Res. 2016 Mar 15;22(6):1469-79. doi: 10.1158/1078-0432.CCR-15-1380. Epub 2015 Nov 20.

14.

Challenges and advances in the assessment of the disposition of antibody-drug conjugates.

Kamath AV, Iyer S.

Biopharm Drug Dispos. 2016 Mar;37(2):66-74. doi: 10.1002/bdd.1957. Epub 2015 Jun 8. Review.

15.

Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax.

Nikolić MZ, Lok LS, Mattishent K, Barth S, Yung B, Cummings NM, Wade D, Vali Y, Chong K, Wilkinson A, Mikolasch T, Brij S, Jenkins HS, Kamath AV, Pasteur M, Hopkins TG, Wason J, Marciniak SJ.

Eur Respir J. 2015 Jun;45(6):1731-4. doi: 10.1183/09031936.00118614. Epub 2015 Mar 18. No abstract available.

16.

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.

Kamath AV, Yip V, Gupta P, Boswell CA, Bumbaca D, Haughney P, Castro J, Tsai SP, Pacheco G, Ross S, Yan M, Damico-Beyer LA, Khawli L, Shen BQ.

MAbs. 2014;6(6):1631-7. doi: 10.4161/mabs.36107.

17.

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.

Kamath AV, Iyer S.

Pharm Res. 2015 Nov;32(11):3470-9. doi: 10.1007/s11095-014-1584-z. Epub 2014 Dec 2. Review.

18.
19.

The structure of XIAP BIR2: understanding the selectivity of the BIR domains.

Lukacs C, Belunis C, Crowther R, Danho W, Gao L, Goggin B, Janson CA, Li S, Remiszewski S, Schutt A, Thakur MK, Singh SK, Swaminathan S, Pandey R, Tyagi R, Gosu R, Kamath AV, Kuglstatter A.

Acta Crystallogr D Biol Crystallogr. 2013 Sep;69(Pt 9):1717-25. doi: 10.1107/S0907444913016284. Epub 2013 Aug 15.

20.

Performance of SOAR (systolic blood pressure, oxygenation, age and respiratory rate) scoring criteria in community-acquired pneumonia: a prospective multi-centre study.

Subramanian DN, Musonda P, Sankaran P, Tariq SM, Kamath AV, Myint PK.

Age Ageing. 2013 Jan;42(1):94-7. doi: 10.1093/ageing/afs158. Epub 2012 Nov 7.

PMID:
23134691
21.

Pharmacokinetics and biodistribution of a human monoclonal antibody to oxidized LDL in cynomolgus monkey using PET imaging.

Kamath AV, Williams SP, Bullens S, Cowan KJ, Stenberg Y, Cherry SR, Rendig S, Kukis DL, Griesemer C, Damico-Beyer LA, Bunting S.

PLoS One. 2012;7(9):e45116. doi: 10.1371/journal.pone.0045116. Epub 2012 Sep 17.

22.

Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.

Kamath AV, Lu D, Gupta P, Jin D, Xin Y, Brady A, Stephan JP, Li H, Tien J, Qing J, Damico-Beyer LA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1071-8. doi: 10.1007/s00280-011-1807-5. Epub 2011 Dec 28.

PMID:
22203368
23.

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.

Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX, Damico-Beyer LA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1063-9. doi: 10.1007/s00280-011-1806-6. Epub 2011 Dec 28.

PMID:
22203367
24.

Prediction of mortality in community-acquired pneumonia in hospitalized patients.

Musonda P, Sankaran P, Subramanian DN, Smith AC, Prentice P, Tariq SM, Kamath AV, Myint PK.

Am J Med Sci. 2011 Dec;342(6):489-93. doi: 10.1097/MAJ.0b013e31822cb95f.

PMID:
21876427
25.

Are shock index and adjusted shock index useful in predicting mortality and length of stay in community-acquired pneumonia?

Sankaran P, Kamath AV, Tariq SM, Ruffell H, Smith AC, Prentice P, Subramanian DN, Musonda P, Myint PK.

Eur J Intern Med. 2011 Jun;22(3):282-5. doi: 10.1016/j.ejim.2010.12.009. Epub 2011 Jan 17.

PMID:
21570648
26.

Confusion, Urea, Respiratory Rate and Shock Index or Adjusted Shock Index (CURSI or CURASI) criteria predict mortality in community-acquired pneumonia.

Myint PK, Musonda P, Sankaran P, Subramanian DN, Ruffell H, Smith AC, Prentice P, Tariq SM, Kamath AV.

Eur J Intern Med. 2010 Oct;21(5):429-33. doi: 10.1016/j.ejim.2010.07.005. Epub 2010 Aug 1.

PMID:
20816599
27.

Performance of CURB-65 and CURB-age in community-acquired pneumonia.

Myint PK, Sankaran P, Musonda P, Subramanian DN, Ruffell H, Smith AC, Prentice P, Tariq SM, Kamath AV.

Int J Clin Pract. 2009 Sep;63(9):1345-50. doi: 10.1111/j.1742-1241.2009.02147.x.

PMID:
19691619
28.

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26.

PMID:
19396600
29.

Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.

Stockman BJ, Kothe M, Kohls D, Weibley L, Connolly BJ, Sheils AL, Cao Q, Cheng AC, Yang L, Kamath AV, Ding YH, Charlton ME.

Chem Biol Drug Des. 2009 Feb;73(2):179-88. doi: 10.1111/j.1747-0285.2008.00768.x.

PMID:
19207420
30.

High-throughput biochemical kinase selectivity assays: panel development and screening applications.

Card A, Caldwell C, Min H, Lokchander B, Hualin Xi, Sciabola S, Kamath AV, Clugston SL, Tschantz WR, Leyu Wang, Moshinsky DJ.

J Biomol Screen. 2009 Jan;14(1):31-42. doi: 10.1177/1087057108326663. Epub 2008 Dec 10.

PMID:
19073965
31.

Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.

Johnson BM, Kamath AV, Leet JE, Liu X, Bhide RS, Tejwani RW, Zhang Y, Qian L, Wei DD, Lombardo LJ, Shu YZ.

Drug Metab Dispos. 2008 Dec;36(12):2475-83. doi: 10.1124/dmd.108.022624. Epub 2008 Sep 11.

PMID:
18787055
32.

Expression, purification and characterization of the human membrane transporter protein OATP2B1 from Sf9 insect cells.

Tschantz WR, Pfeifer ND, Meade CL, Wang L, Lanzetti A, Kamath AV, Berlioz-Seux F, Hashim MF.

Protein Expr Purif. 2008 Feb;57(2):163-71. Epub 2007 Oct 17.

PMID:
18024077
33.

Simple modification of CURB-65 better identifies patients including the elderly with severe CAP.

Myint PK, Kamath AV, Vowler SL, Harrison BD.

Thorax. 2007 Nov;62(11):1015-6; author reply 1016. No abstract available.

34.

Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: use of Caco-2 and Calu-3 cells.

Kamath AV, Morrison RA, Mathias NR, Dando SA, Marino AM, Chong S.

Arch Pharm Res. 2007 Aug;30(8):1002-7.

PMID:
17879754
35.

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Kamath AV, Wang J, Lee FY, Marathe PH.

Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. Epub 2007 Apr 11.

PMID:
17429625
36.

Expression and protein chemistry yielding crystallization of the catalytic domain of ADAM17 complexed with a hydroxamate inhibitor.

Hoth LR, Tan DH, Wang IK, Wengender PA, Thompson MA, Kamath AV, Geoghegan KF.

Protein Expr Purif. 2007 Apr;52(2):313-9. Epub 2006 Nov 7.

PMID:
17169570
37.

Role of bronchoscopy in early diagnosis of lung cancer.

Kamath AV, Chhajed PN.

Indian J Chest Dis Allied Sci. 2006 Oct-Dec;48(4):265-9. Review.

PMID:
16970293
38.

Is it time to rethink the urea criterion in CURB-65?

Kamath AV, Myint PK, Vowler SL, Harrison BD.

Eur Respir J. 2006 Jun;27(6):1321-2. No abstract available.

39.

Recognizing and managing severe community-acquired pneumonia.

Kamath AV, Myint PK.

Br J Hosp Med (Lond). 2006 Apr;67(4):M76-8. Review. No abstract available.

PMID:
16681312
41.

A new chemical tool for exploring the physiological function of the PDE2 isozyme.

Chambers RJ, Abrams K, Garceau NY, Kamath AV, Manley CM, Lilley SC, Otte DA, Scott DO, Sheils AL, Tess DA, Vellekoop AS, Zhang Y, Lam KT.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):307-10. Epub 2005 Nov 3.

PMID:
16275071
42.

A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.

Chambers RJ, Abrams K, Castleberry TA, Cheng JB, Fisher DA, Kamath AV, Marfat A, Nettleton DO, Pillar JD, Salter ED, Sheils AL, Shirley JT, Turner CR, Umland JP, Lam KT.

Bioorg Med Chem Lett. 2006 Feb;16(3):718-21. Epub 2005 Nov 2.

PMID:
16263279
43.

Is the neutrophil the key effector cell in severe asthma?

Kamath AV, Pavord ID, Ruparelia PR, Chilvers ER.

Thorax. 2005 Jul;60(7):529-30. No abstract available.

44.

Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.

Iffland A, Kohls D, Low S, Luan J, Zhang Y, Kothe M, Cao Q, Kamath AV, Ding YH, Ellenberger T.

Biochemistry. 2005 Jun 14;44(23):8312-25.

PMID:
15938621
45.

Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.

Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH.

Cancer Chemother Pharmacol. 2005 Aug;56(2):145-53. Epub 2005 Apr 14.

PMID:
15830240
46.
47.

Microbiological profile of community-acquired pneumonia in adults over the last 20 years.

Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD.

J Infect. 2005 Feb;50(2):107-13.

PMID:
15667910
48.
49.

Effect of fruit juices on the oral bioavailability of fexofenadine in rats.

Kamath AV, Yao M, Zhang Y, Chong S.

J Pharm Sci. 2005 Feb;94(2):233-9.

PMID:
15570603
50.

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.

Kamath AV, Chong S, Chang M, Marathe PH.

Cancer Chemother Pharmacol. 2005 Feb;55(2):110-6. Epub 2004 Aug 27.

PMID:
15338193

Supplemental Content

Loading ...
Support Center